These results imply that GLP-1R-targeted therapies could be potentially used to treat neurodegenerative diseases, including diseases like Alzheimer’s and Parkinson’s as well as neuropathic pain and cancer [10,45]. This evidence concerns the gene GLP1R and Parkinson disease.